Basic Information
RNALocate ID: RLID:11001575
RNA Symbol: hsa-miR-200b-3p
Localization: Microvesicle
RNA Information
RNA Name: hsa-miR-200b
RNA ID: miRBase:MIMAT0000318
RNA Category: miRNA
Species: Homo sapiens
Sequence:
Localization Information
PubMed ID: 23539611
Tissue/Cell Line: Seminal plasma
Method: Microarray
Description: In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4.
Other Subcellular Localization
RNALocate ID Localization Tissue/Cell line PubMed ID
RLID:01001685 Cytoplasm Colon cancer cells 20864815
RLID:01001686 Nucleolus Breast adenocarcinoma cells (MCF-7) 24918059
RLID:11001571 Exosome Urine 26576778
RLID:11001572 Exosome Breast cancer cell line (MCF-7) 20976003
RLID:11001573 Exosome Brain tissue 23382797
RLID:11001574 Exosome Plasma 23663360
RLID-D:11000067 Exosome Breast milk|Colon tissue|Seminal fluid|Tongue tissue
RLID-D:11000341 Microvesicle Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine
ncRNA Disease Information
Resource RNA Symbol Disease Link
MNDR hsa-miR-200b-3p Splenic marginal zone lymphoma MNDR-E-MI-26092
MNDR hsa-miR-200b-3p Multiple sclerosis chronic progressive MNDR-E-MI-26093
MNDR hsa-miR-200b-3p Tongue squamous cell carcinoma MNDR-E-MI-26094
MNDR hsa-miR-200b-3p Oral squamous cell carcinoma MNDR-E-MI-26095
MNDR hsa-miR-200b-3p Large cell neuroendocrine cancer MNDR-E-MI-26096
MNDR hsa-miR-200b-3p Medulloblastoma MNDR-E-MI-26097
MNDR hsa-miR-200b-3p Mucosa-associated lymphoid tissue lymphoma MNDR-E-MI-26098
MNDR hsa-miR-200b-3p High-grade serous ovarian carcinoma MNDR-E-MI-26099
MNDR hsa-miR-200b-3p Ovarian clear cell carcinoma MNDR-E-MI-26100
MNDR hsa-miR-200b-3p Uterine corpus endometrial carcinoma MNDR-E-MI-26101
MNDR hsa-miR-200b-3p Lymphoma non-hodgkin MNDR-E-MI-26102
MNDR hsa-miR-200b-3p Estrogen-receptor positive breast cancer MNDR-E-MI-26103
MNDR hsa-miR-200b-3p Estrogen-receptor negative breast cancer MNDR-E-MI-26104
MNDR hsa-miR-200b-3p Progesterone-receptor positive breast cancer MNDR-E-MI-26105
MNDR hsa-miR-200b-3p Progesterone-receptor negative breast cancer MNDR-E-MI-26106
MNDR hsa-miR-200b-3p Her2-receptor positive breast cancer MNDR-E-MI-26107
MNDR hsa-miR-200b-3p Triple negative breast cancer MNDR-E-MI-26108
MNDR hsa-miR-200b-3p Breast cancer luminal MNDR-E-MI-26109
MNDR hsa-miR-200b-3p Androgen-independent prostate cancer MNDR-E-MI-26110
MNDR hsa-miR-200b-3p Gastric cancer MNDR-E-MI-26111
MNDR hsa-miR-200b-3p Gastric lymphoma MNDR-E-MI-26112
MNDR hsa-miR-200b-3p Alzheimer disease MNDR-E-MI-26113
MNDR hsa-miR-200b-3p Bladder cancer MNDR-E-MI-26114
MNDR hsa-miR-200b-3p Head and neck cancer MNDR-E-MI-26115
MNDR hsa-miR-200b-3p Ataxia telangiectasia MNDR-E-MI-26116
MNDR hsa-miR-200b-3p Cardiovascular disease MNDR-E-MI-26117
MNDR hsa-miR-200b-3p Lung cancer MNDR-E-MI-26118
MNDR hsa-miR-200b-3p Endometrial cancer MNDR-E-MI-26119
MNDR hsa-miR-200b-3p Parkinson disease MNDR-E-MI-26120
MNDR hsa-miR-200b-3p Basal-like breast cancer MNDR-E-MI-26121
MNDR hsa-miR-200b-3p Cancer MNDR-E-MI-26122
MNDR hsa-miR-200b-3p Thyroid cancer MNDR-E-MI-26123
MNDR hsa-miR-200b-3p Pituitary neoplasms MNDR-E-MI-26124
MNDR hsa-miR-200b-3p Pancreatic cancer MNDR-E-MI-26125
MNDR hsa-miR-200b-3p Melanoma MNDR-E-MI-26126
MNDR hsa-miR-200b-3p Rectum adenocarcinoma MNDR-E-MI-26127
MNDR hsa-miR-200b-3p Nephroblastoma MNDR-E-MI-26128
MNDR hsa-miR-200b-3p Colon cancer MNDR-E-MI-26129
MNDR hsa-miR-200b-3p Ischemic attack transient MNDR-E-MI-26130
MNDR hsa-miR-200b-3p Colon adenocarcinoma MNDR-E-MI-26131
MNDR hsa-miR-200b-3p Multiple sclerosis relapsing-remitting MNDR-E-MI-26132
MNDR hsa-miR-200b-3p Familial ovarian cancer MNDR-E-MI-26133
MNDR hsa-miR-200b-3p Acromegaly MNDR-E-MI-26134
MNDR hsa-miR-200b-3p Kidney cancer MNDR-E-MI-26135
MNDR hsa-miR-200b-3p Endometrial adenocarcinoma MNDR-E-MI-26136
MNDR hsa-miR-200b-3p Endometrial endometrioid carcinoma MNDR-E-MI-26137
MNDR hsa-miR-200b-3p Endometriosis MNDR-E-MI-26138
MNDR hsa-miR-200b-3p Carcinoma ductal breast MNDR-E-MI-26139
MNDR hsa-miR-200b-3p Glioblastoma MNDR-E-MI-26140
MNDR hsa-miR-200b-3p Astrocytoma MNDR-E-MI-26141
MNDR hsa-miR-200b-3p Glioma MNDR-E-MI-26142
MNDR hsa-miR-200b-3p Amyotrophic lateral sclerosis MNDR-E-MI-26143
MNDR hsa-miR-200b-3p Breast carcinoma MNDR-E-MI-26144
MNDR hsa-miR-200b-3p Uterine cancer MNDR-E-MI-26145
MNDR hsa-miR-200b-3p Cervical adenocarcinoma MNDR-E-MI-26146
MNDR hsa-miR-200b-3p Gastric adenocarcinoma MNDR-E-MI-26147
MNDR hsa-miR-200b-3p Cervical squamous cell carcinoma MNDR-E-MI-26148
MNDR hsa-miR-200b-3p Pituitary adenoma MNDR-E-MI-26149
MNDR hsa-miR-200b-3p Lung squamous cell carcinoma MNDR-E-MI-26150
MNDR hsa-miR-200b-3p Carcinoma lung non-small-cell MNDR-E-MI-26151
MNDR hsa-miR-200b-3p Lung adenocarcinoma MNDR-E-MI-26152
MNDR hsa-miR-200b-3p Ovarian carcinoma MNDR-E-MI-26153
MNDR hsa-miR-200b-3p Bladder urothelial carcinoma MNDR-E-MI-26154
MNDR hsa-miR-200b-3p Pancreatic adenocarcinoma MNDR-E-MI-26155
MNDR hsa-miR-200b-3p Carcinoma renal cell MNDR-E-MI-26156
MNDR hsa-miR-200b-3p Kidney renal papillary cell carcinoma MNDR-E-MI-26157
MNDR hsa-miR-200b-3p Clear cell renal cell carcinoma MNDR-E-MI-26158
MNDR hsa-miR-200b-3p Allergic rhinitis MNDR-E-MI-26159
MNDR hsa-miR-200b-3p Biliary tract cancer MNDR-E-MI-26160
MNDR hsa-miR-200b-3p Intrahepatic cholangiocarcinoma MNDR-E-MI-26161
MNDR hsa-miR-200b-3p Cholangiocarcinoma MNDR-E-MI-26162
MNDR hsa-miR-200b-3p Lung small cell carcinoma MNDR-E-MI-26163
MNDR hsa-miR-200b-3p Gastric carcinoma MNDR-E-MI-26164
MNDR hsa-miR-200b-3p Testicular germ cell cancer MNDR-E-MI-26165
MNDR hsa-miR-200b-3p Growth hormone-secreting pituitary adenoma MNDR-E-MI-26166
MNDR hsa-miR-200b-3p Adenoma MNDR-E-MI-26167
MNDR hsa-miR-200b-3p Breast invasive carcinoma MNDR-E-MI-26168
MNDR hsa-miR-200b-3p Hepatocellular carcinoma MNDR-E-MI-26169
MNDR hsa-miR-200b-3p Familiar ovarian carcinoma MNDR-E-MI-26170
MNDR hsa-miR-200b-3p B-cell lymphoma MNDR-E-MI-26171
MNDR hsa-miR-200b-3p Malignant pleural mesothelioma MNDR-E-MI-26172
MNDR hsa-miR-200b-3p Periodontitis MNDR-E-MI-26173
MNDR hsa-miR-200b-3p Hodgkin lymphoma MNDR-E-MI-26174
MNDR hsa-miR-200b-3p Ulcerative colitis MNDR-E-MI-26175
MNDR hsa-miR-200b-3p Burkitt lymphoma MNDR-E-MI-26176
MNDR hsa-miR-200b-3p Crohn disease MNDR-E-MI-26177
MNDR hsa-miR-200b-3p Skin cutaneous melanoma MNDR-E-MI-26178
MNDR hsa-miR-200b-3p Skin melanoma MNDR-E-MI-26179
MNDR hsa-miR-200b-3p Acute myelogenous leukemia MNDR-E-MI-26180
MNDR hsa-miR-200b-3p Colorectal cancer MNDR-E-MI-26181
MNDR hsa-miR-200b-3p Multiple myeloma MNDR-E-MI-26182
MNDR hsa-miR-200b-3p Type 1 diabetes mellitus MNDR-E-MI-26183
MNDR hsa-miR-200b-3p Ovarian epithelial cancer MNDR-E-MI-26184
MNDR hsa-miR-200b-3p Autoimmune diseases MNDR-E-MI-26185
MNDR hsa-miR-200b-3p Graft vs host disease MNDR-E-MI-26186
MNDR hsa-miR-200b-3p Prostatic neoplasms MNDR-E-MI-26187
MNDR hsa-miR-200b-3p Chronic pain MNDR-E-MI-26188
MNDR hsa-miR-200b-3p Breast cancer her3+ negative MNDR-E-MI-26189
MNDR hsa-miR-200b-3p Cholestatic liver injury MNDR-E-MI-26190
MNDR hsa-miR-200b-3p Solid-pseudopapillary neoplasm of pancreas MNDR-E-MI-26191
MNDR hsa-miR-200b-3p Tubulovillous adenoma MNDR-E-MI-26192
RNA Interaction Information
Resource RNA Symbol Species Link RNALocate ID
RNAInter ADAM12 Homo sapiens RR00040359
TOP